BaumgartnerAStichORauerS. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab. Int J Neurosci2012; 122: 35–39.
2.
KerbratALe PageELerayE. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci2011; 308: 98–102.
3.
DaelmanLMaitrotAMaaroufA. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler2012; 18: 1647–1649.
4.
JanderSTurowskiBKieseierBC. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler2012; 18: 1650–1652.
5.
RinaldiFSeppiDCalabreseM. Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: Clinical and magnetic resonance imaging findings. Mult Scler2012; 18: 1640–1643.
